Skip to main content
. Author manuscript; available in PMC: 2011 Dec 3.
Published in final edited form as: J Proteome Res. 2010 Oct 22;9(12):6368–6379. doi: 10.1021/pr100666c

Figure 1. TDP-43 pathology observed in FTLD and phosphopeptide enrichment strategy.

Figure 1

Immunohistochemical analyses of FTLD and control cases using a pan-TDP-43 (A and B) or a phosphospecific TDP-43 Ser(409/410) antibody in FTLD (C). (D) Flowchart of experimental design to enrich phosphopeptides from human brain tissue. IHC, immunohistochemistry.